Istradefylline Further Down But Still Not Quite Out In Parkinson’s?
Executive Summary
Despite the long and troubled history of the molecule, Kyowa Hakko Kirin has persisted with the development of istradefylline for Parkinson's disease, but a new Phase III failure might be the last straw for the A2a antagonist.
You may also be interested in...
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Newron's Parkinson's Disease Drug Xadago Priced At $600-700/Month
First new chemical entity for Parkinson's to clear FDA in 10 years, Xadago has a narrower indication than Teva's Azilect and similar pricing.
Newron's Parkinson's Drug Xadago Has Narrower Indication Than Teva's Azilect
After overcoming regulatory hurdles, Newron may have tough time competing in US against market stalwart Azilect; eight Parkinson's drugs are in Phase III trials.